Introduction: Conceptualization of Neuroinflammation and Its Relationships With Neuropsychiatric Disorders
==========================================================================================================

Framework for Neuroinflammation in CNS Pathologies
--------------------------------------------------

Immunopsychiatry is a renewed biomedical discipline in continuous expansion that studies the interaction/s between the brain and the immune system. It is aimed to find new molecular/cellular targets for the development of original therapies for the treatment of psychiatric disorders ([@B131]; [@B91]). It is based on increasing evidences from both preclinical and clinical studies supporting the existence of a "low grade" neuroinflammatory response with relevance in the etiophysiopathology of psychiatric disorders \[recently reviewed in [@B11]\]. In particular cases such as schizophrenia and other psychotic diseases, this neuroinflammation has been demonstrated by means of brain *postmortem* evidence and imaging techniques, although some authors have alerted about the need for more selective markers of glial activation and the combination with diverse methodologies at molecular/cellular level ([@B180]; [@B121]). Positron emission tomography (PET) imaging and *postmortem* evidences are also extended to major depression, bipolar disorder, autism spectrum disorder, and drug abuse, but also with some degrees of controversy ([@B184]; [@B113]; [@B92]).

Neuroinflammation is defined as the homeostatic response of the central nervous system (CNS) against injury. It presents shared characteristics with peripheral inflammation but also retains specific features, such as the existence of the brain--blood barrier (BBB) and the cerebrospinal fluid, or the activation of glial cells. Neuroinflammation is a hot topic in the study of CNS pathologies and, recently, some authors have tried to redefine and to delimitate the concept, paying special attention to the whole process different roles (homeostatic vs. detrimental), triggers, and degrees of severity ([@B47]). One fundamental consideration is that classical inflammatory-related cells or mediators, such as microglia or cytokines, can regulate physiological processes in the CNS not always strictly related to neuroinflammation ([@B50]).

One consensus idea is that the neuroinflammatory response is a necessary process for coping with any type of injury ([@B70]), but may become deleterious in severe, non-controllable, and/or long-lasting conditions ([@B20]).

In particular, the concomitant and/or exclusive overproduction and activity of pro-inflammatory mediators such as cytokines \[tumor necrosis factor alpha (TNF-α), interleukin 1beta (IL-1β), and IL-6\], chemokines \[monocyte chemoattractant protein 1 (MCP-1/CCL2) and fractalkine (CX3CL1)\], prostaglandins \[prostaglandin E~2~ (PGE2)\], kinases \[extracellular signal-regulated kinase, c-Jun N-terminal kinase, mitogen-activated protein kinase (MAPK)\], pattern recognition receptors (PRR) \[toll-like receptors (TLR)\], nuclear factors \[nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1)\], signal transducer and activator of transcription (STAT), and enzymes \[cyclooxygenases (COX), inducible NO synthase (iNOS)\] could lead to alterations in the normal structure and function of the CNS.

Thus, the neuroinflammatory response has been related to neurodegeneration by oxidative/nitrosative stress, neurodevelopment, neuroplasticity and cellular metabolism, survival, and differentiation ([@B126]; [@B96]; [@B193]; [@B42]). At the end, all these alterations can even affect other multifaceted processes, such as monoaminergic and glutamatergic neurotransmission ([@B123]), neuroendocrine responses ([@B132]), cognition ([@B168]), and ultimately behavior ([@B41]; [@B112]).

Regulation of Neuroinflammation and Trigger Mechanisms
------------------------------------------------------

The neuroinflammatory response must be finely regulated to avoid its deleterious consequences. In response to immune activation endogenous anti-inflammatory and antioxidant mechanisms are activated in the CNS. There are three mechanisms that are currently receiving especially attention: (1) Synthesis of the cyclopentenone prostaglandin 15-deoxy-PGJ~2~ (15d-PGJ~2~) ([@B143]). This is the proposed endogenous ligand for the gamma isoform of peroxisome proliferator-activated nuclear receptors (PPARγ), a transcription factor whose main effect is to mitigate inflammation by repressing NF-κB signaling ([@B62]). PPARγ may be pharmacologically activated by the antidiabetic drugs thiazolidinediones, which exert anti-inflammatory, anti-excitotoxic, and pro-energetic effects in the brain ([@B62]); (2) The activation of the antioxidant pathway orchestrated by the nuclear transcription factor (erythroid-derived 2)-like 2 (NRF2). In presence of oxidative stress signals, NRF2 translocates into the nucleus where it binds to consensus sequences of antioxidants response elements (ARE). ARE encode a wide variety of antioxidant enzymes including some dedicated to glutathione synthesis and to the elimination of oxygen reactive species ([@B197]); and (3) polarization of microglia to the anti-inflammatory phenotype M2. M2 microglia secretes anti-inflammatory cytokines such as the transforming growth factor beta (TGFβ) and IL10 ([@B82]). Increased M2 profile could provide neuroprotection under CNS pathological conditions, and its modulation is emerging as a promising target in neuropsychiatric diseases ([@B149]).

Another important neuroinflammation-related topic to explain whether immune activation is a neuropsychiatric etiological factor or just an epiphenomenon is the study of its triggering mechanism/s. The nature and extent of the immune activation depend on whether it is caused by endogenous or exogenous factors, but the physiopathological consequences appear to be directly related to the precise moment of this activation. This area of research is especially focused on the study of the innate immune TLRs family. TLRs belong to the super-family of PRRs that detect conserved pathogen-associated molecular patterns (PAMPs) ([@B1]). The canonical example of PAMPs is the endotoxin lipopolysaccharide (LPS) (Phelps et al.) from the outer membrane of Gram-negative bacteria ([@B141],[@B142]). LPS is recognized by TLR4, the first member of the family described in humans ([@B114]).

Toll-like receptors also recognize multiple endogenous ligands, released as cellular or tissue danger/damage signals, named damage-associated molecular patterns (DAMPs) or alarmins ([@B164]). In the case of TLR4, the best described DAMPs are fibrinogen, heat shock proteins 60--70 (HSP60-70), and high-mobility-group box protein 1 (HMGB-1) ([@B139]). The implication of DAMPs in the process called "sterile inflammation" supports the view of TLR4 as a ubiquitous sentinel receptor and some authors have remarked the importance of such subtype of neuroinflammation in psychiatric disorders ([@B148]). Indeed, in the last years, some evidence suggests a role of TLR4 in stress and stress-related neuropsychiatric diseases ([@B61]). There are several mechanisms related to TLRs activation in neuropsychiatric diseases that deserve further investigation: (1) bacterial translocation of the Gram-negative enterobacteria ("leaky gut"). Increased intestinal barrier permeability and bacterial translocation have been reported in patients with major psychiatric disorders. Patients also present an altered microbiome and, in some cases, intestinal inflammation ([@B89]); (2) prenatal infection (bacteria, virus, and protozoa) induced maternal immune activation (MIA)/inflammation and the resultant oxidative/nitrosative stress. In this way, an infection during the gestational period is a risk factor for developing psychiatric disease in the progeny over the course of a lifetime ([@B51]). This idea of early immune-dependent alterations in the neurodevelopment supports the use of animal models based on MIA and other prenatal stressors exposure for the study of psychiatric disease ([@B106]; [@B116]); and (3) other possible sources of activation of the innate immune system have been recently suggested for major depressive disorder and could be extended to other psychiatric diseases. These include psychosocial stressors, physical inactivity, obesity, smoking, poor dental care or overall hygiene, and sleep deprivation ([@B14]).

Approaches to Study Neuroinflammatory-Based Conditions
------------------------------------------------------

The study of the inflammatory response in psychiatric disease is actively focusing on the search of new diagnostics to monitor the natural course of the disease (trait or state biomarkers, risk/protection factors) ([@B98]; [@B179]; [@B161]). However, finding a unique *golden marker* for the different neuropsychiatric pathologies is greatly difficult and challenging due to the heterogeneity of complex mental disorders, the unspecific nature of the inflammatory response, and the great number of confounding factors that trigger immune alterations (psychological stress exposure, treatment, metabolic and other co-morbid conditions, diet, age, latent infections, use and abuse of psychoactive drugs, etc.). The most logical approach is to study all the elements of an inflammatory pathway, including the regulatory mechanisms and their relationship with symptomatology, through the use of synergic methodology, such as fMRI, brain morphometry, *postmortem* studies, cognitive assessments, peripheral biomarkers, and genetic/epigenetic studies ([@B96]).

In spite of the existent gaps in the knowledge of the precise role of neuroinflammation in the etiophysiopathology of neuropsychiatric disorders, there is an increasing number of clinical trials evaluating the use of classical anti-inflammatory/antioxidant agents as a co-adjuvant strategy to current pharmacological treatments. Some of these agents are nonsteroidal anti-inflammatory drugs (NSAIDs), selective COX-2 inhibitors (COXIBs), cytokine antagonists, omega-3 polyunsaturated fatty acids, prebiotics, probiotics, minocycline, and *N*-acetylcysteine ([@B88]; [@B154]; [@B84]). In general, only modest clinical effects have been reported with compounds capable of blocking different pro-inflammatory pathways, suggesting the need to explore new compounds and combined strategies. Specifically, the change of paradigm toward the use of compounds that enhance the existent endogenous anti-inflammatory mechanisms, such as the activation of PPAR isoforms that function as transcription factors, has gained special attention in the last years ([@B63]; [@B152]; [@B34]).

In this sense, this review introduces the role of endogenous compounds such as the acylethanolamides as anti-inflammatory agents and their potential to treat neuropsychiatric disorders. Within the neuropsychiatric disorders, here we focus on the alcoholic pathology and, specifically, we revise the exiting evidence of the compound oleoylethanolamide (OEA) to modulate alcohol abuse-induced neuroinflammation.

Alcohol Abuse and Neuroinflammation
===================================

Alcohol-Use Disorder as a CNS Pathology With a Neuroinflammatory Component
--------------------------------------------------------------------------

According to the World Health Organization and the National Institute on Drug Abuse (NIDA), addiction is conceptualized as a chronic and recurrent disease of the CNS. Repeated use and abuse of drugs may induce an addiction disorder and, among all drugs of abuse, alcohol is one of the most widely used psychoactive drugs worldwide, whose consumption originates major public health problems in our society, including addiction. Although many individuals regularly consume alcohol in moderate doses with no significant adverse consequence, a substantial number drink alcohol in abuse patterns, such as binge drinking. Binge drinking is a common abuse pattern among adolescents and young adults, and it is defined as a short-term pattern of consumption (four or five drinks in about 2 h) that increases the blood alcohol concentration above 80 mg/dl ([@B120]). Chronic alcohol consumption, especially in binge drinking episodes, contributes to several medical complications as well as to a higher risk of developing alcohol-use disorders (AUDs).

Alcohol binge drinking and chronic alcohol consumption are associated with the induction of neuroinflammation ([@B122], XX), and growing body of evidence suggests that this neuroinflammatory process may contribute to alcohol-induced brain damage and neurodegeneration ([@B183]; [@B74]; [@B37]; [@B175]). Moreover, this inflammation-induced damage caused by alcohol abuse is associated with the development of cognitive and behavioral impairments in preclinical studies ([@B134]). In humans, blood peripheral inflammatory markers have been associated with alcohol abuse, specifically bingeing or intoxication ([@B127]; [@B136]) and neuroinflammatory components have been detected in human postmortem brains of alcoholics ([@B155]).

Role of TLR4 in Alcohol-Induced Neuroinflammation
-------------------------------------------------

Toll-like receptors are a family of receptors involved in the regulation of innate immune responses to infections and CNS injury ([@B86]; [@B125]) comprising 10 members in humans and 12 in mice ([@B24]). Among them, TLR2, TLR3, and TLR4 are up-regulated in the frontal cortex of *postmortem* AUD patients as well as in the cortex of mice chronically treated with alcohol ([@B39]). Alcohol also induces the expression of TLR7 in the hippocampus of *postmortem* AUD patients and in rat brain slice culture after alcohol treatment ([@B32]). TLR4 is one of the innate immune receptors receiving more attention in the context of neuroinflammation-associated neuropsychiatric disorders. Growing evidence suggests that the activation of TLR4 signaling plays an important role in the pathogenesis of alcohol-induced inflammatory brain damage. Thus, it has been shown that alcohol activates TLR4 response in brain, astrocytes, microglia, and macrophages ([@B21]; [@B54], [@B55]; [@B146]; [@B2]). Moreover, it has been reported the absence of inflammatory response in microglia of TLR4-deficient mice after alcohol treatment ([@B55]). Similarly, the knockdown of the expression of TLR4 inhibits the production of pro-inflammatory mediators by blocking the activation of MAPK and NF-κB pathways in astrocytes ([@B2]). The activation of TLR4 also plays an important role in the behavioral and cognitive dysfunctions associated with alcohol-induced neuroinflammation damage since these deficits, such as memory impairments and anxiety-like behaviors, are not observed in TLR4-deficient mice after alcohol treatment ([@B134]).

Alcohol-Induced HMGB1 Activates TLR4
------------------------------------

Damage-associated molecular patterns are endogenous agonists of TLRs that are involved in numerous non-infectious neurological disorders, including AUDs ([@B38]). Among these endogenous TLR4 agonists, HMGB1 is a pro-inflammatory signal that plays a key role in AUDs. In rats, alcohol exposure during adolescence activates HMGB1/TLR4 danger signaling in the brain, and this activation persists into adulthood correlating with the presence of cognitive deficits ([@B187]). Other studies in rodents have shown that chronic alcohol treatment increases HMGB1 in cortex and cerebellum ([@B39]; [@B97]), and cortical HMGB1 is also upregulated after alcohol binges ([@B5]). Additionally, young female regular alcohol binge drinkers show elevated HMGB1 in plasma ([@B6]) and the expression of HMGB1 is increased in the frontal cortex of *postmortem* AUD patients ([@B39]). The activation of HMGB1 by alcohol causes its translocation from the nucleus, and then, it is released from neurons to the extracellular space triggering alcohol-induced neuroimmune signaling through direct binding to both glial and neuronal TLR4 ([@B203]). The activation of microglial TLR4 by HMGB1 also induces the expression and release of more HMGB1 from neurons, which magnifies the inflammatory response ([@B203]).

In addition to TLR4 signaling pathway, HMGB1 can also bind and activate other targets, such as other TLRs and the receptor for advanced glycation end products (RAGE) ([@B133]; [@B189]). The expression of RAGE is up-regulated in the *postmortem* brain of AUD patients and correlates with an early age of drinking ([@B188]). Increased brain HMGB1 levels have been associated with cognitive deficits, effects that are mediated through both TLR4 and RAGE receptors ([@B109]). A recent study reports that HMGB1/IL-1β heterodimer contributes to the immune activation induced by alcohol ([@B33]). In fact, an increase of HMGB1/IL-1β complexes was found in the hippocampus of mice after an acute binge alcohol treatment and in *postmortem* tissue of AUD patients ([@B33]).

NF-κB Canonical Pro-inflammatory Signaling Pathway
--------------------------------------------------

Toll-like receptors belong to a large superfamily that includes the interleukin-1 receptors (IL-1Rs) ([@B1]), and the activation of these receptors contributes to the neuroinflammation process ([@B29]). The activation of IL-1Rs and TLRs induces, via myeloid differentiation factor 88 (Myd88)-dependent pathway, the recruitment of downstream signaling molecules, including IL-1R-associated kinase ([@B117]), tumor necrosis factor receptor-associated factor 6 (TRAF6), and the NF-κB-inducing kinase ([@B1]). The recruitment of these molecules triggers the stimulation of signaling pathways, including the MAPK pathway, and the activation of transcriptional factors, such as the NF-κB and the AP-1, which lead to the induction of genes encoding inflammation-associated molecules and cytokines ([@B1]).

The transcription factor NF-κB plays a key role in alcohol-induced neuroinflammation. Alcohol activates NF-κB in the rat brain ([@B191]), and *in vivo* and *in vitro* studies have shown that alcohol increases the NF-κB-DNA binding ([@B37]; [@B201], [@B202]), inducing the transcription of multiple pro-inflammatory genes, such as IL-1β, TNF-α, MCP-1, COX-2, or iNOS ([@B183]; [@B21]; Figure [1](#F1){ref-type="fig"}). The induction of COX-2 by alcohol involves a TLR4-mediated signaling, since chronic alcohol-induced up-regulation of COX-2 is not observed in TLR4 knockout mice ([@B2]), and alcohol-induced COX-2 and iNOS upregulation has been associated to cell death ([@B21]; [@B5]).

![Scheme of convergent Toll-like receptor 4 (TLR-4) activating pathways after ethanol (EtOH) exposure. EtOH is a direct agonist of TLR4 and can also activate it through the induction of PAMPs, such as bacterial LPS (Phelps et al.), or DAMPs, such as high mobility group box 1 protein (HMGB1). Abbreviations: MD-2, lymphocyte antigen 96; MyD88, myeloid differentiation primary response 88; NF-κB, nuclear factor kappa B; IκB, inhibitor of κB; IKK, inhibitor κB kinase; IKK-p, phosphorylated inhibitor κB kinase; TNF-α, tumor necrosis factor alpha; IL1β, interleukin 1beta; MCP-1, monocyte chemoattractant protein-1; iNOS, inducible NO synthase; COX-2, cyclooxygenase 2; MDA, malondialdehyde; 4-HNE, 4-hydroxynonenal.](fnmol-11-00490-g001){#F1}

Additionally, COX-2 and iNOS play a key role in the alcohol-induced inflammatory brain damage during adolescence ([@B135]). Additionally, the expression of NF-κB is associated to alcohol preference in rodents ([@B119]), while in humans, a variation in NF-κB1 is linked to increased risk of AUD ([@B49]).

Role of Oxidative Stress in Alcohol-Induced Neuroinflammation
-------------------------------------------------------------

In addition to the NF-κB-signaling pathway, another innate immune gene activated by alcohol is the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, an enzyme that produces reactive oxygen species (ROS), inducing oxidative stress and contributing to cell damage ([@B146]; [@B145]). The activation of this enzyme is involved in the pathology of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease ([@B165]; [@B194]; [@B102]). Previous studies have found an activation of NADPH oxidase and an increase in the production of ROS in the orbitofrontal cortex of *postmortem* AUD patients as well as in mice after a chronic alcohol treatment ([@B145]). The production of ROS is also associated with the activation of NF-κB transcription, contributing to an amplification of the pro-inflammatory cascade ([@B40]). However, the administration of the antioxidant butylated hydroxytoluene reduces the NF-κB-DNA binding induced by alcohol, blocking the activation of this transcription factor and preventing the neuroinflammation ([@B37]; [@B202]). Several studies from [@B176], [@B175]) have described the alteration of pro-oxidative pathways associated to neuroinflammation after binge alcohol treatment, and these affects are prevented by docosahexaenoic acid. These pathways include the protein aquaporin-4 (AQP4) water channel as well as the neuroinflammation-linked enzymes: key phospholipase A2 (PLA2) family members and poly (ADP-ribose) polymerase 1 (PARP-1). AQP4 is expressed mainly in astroglia and is involved in the regulation of cellular brain edema, playing a key role in the neuroinflammation process ([@B156]; [@B60]). Previous *in vitro* studies have shown that repetitive alcohol intoxication bouts increase AQP4 levels ([@B171]). Therefore, oxidative stress is involved in alcohol-induced brain damage, and the use of drugs with antioxidant effects may be an effective treatment against the neuroinflammation and neurodegeneration induced by alcohol.

Oleoylethanolamide Is a Member of the Anti-Inflammatory and Neuroprotectant Acylethanolamide Family
===================================================================================================

The acylethanolamides (also known as *N*-acylethanolamines) are a class of naturally occurring lipid mediators involved in the regulation of a great deal of homeostatic functions ([@B128]). The endocannabinoid AEA is structurally an acylethanolamide, and other bioactive acylethanolamides are the anorexic lipid mediator OEA ([@B151]) and the anti-nociceptive mediator palmitoylethanolamide (PEA) ([@B26]; Figure [2](#F2){ref-type="fig"}). In this review, we will summarize the anti-inflammatory and neuroprotectant actions of these three acylethanolamides and we will focus on the specific role of OEA in neuroinflammation and alcohol abuse.

![Chemical structure of the acylethanolamides anandamide (AEA), oleoylethanolamide (OEA), and palmitoylethanolamide (PEA), and pathways for their synthesis, degradation, and oxidation. Abbreviations: NAT, Ca^2+^-dependent *N*-acyltransferase; iNAT, Ca^2+^-independent NAT; NAPE, *N*-acylphosphatidylethanolamine; NAPE-PLD, NAPE-hydrolyzing phospholipase D; ABDH4, α/β-hydrolase domain-containing protein 4; GDE, glycerophosphodiesterase; NAE, acylethanolamide (*N*-acylethanolamine); AEA, anandamide (*N*-arachidonoylethanolamine); OEA, oleoylethanolamide (*N*-oleoylethanolamine); PEA, palmitoylethanolamide (*N*-palmitoylethanolamine); COX-2, cyclooxygenase-2; FAAH, fatty acid amide hydrolase; NIAAA, *N*-acylethanolamine-hydrolyzing acid amidase; LOX, lipoxygenase.](fnmol-11-00490-g002){#F2}

Synthesis, Degradation, and Receptor Binding of Acylethanolamides
-----------------------------------------------------------------

Despite of the fact that acylethanolamides are widely divergent in function, they share common synthesis and inactivation pathways ([@B58]; Figure [2](#F2){ref-type="fig"}). Acylethanolamides are composed of a fatty acid and ethanolamine. Fatty acids can be synthesized within the brain, but polyunsaturated fatty acids are mainly supplied by the blood. From the diet, some fatty acids are incorporated to the blood as precursors of other polyunsaturated fatty acids such arachidonic acid (AA) ([@B12]). Many of these fatty acids are largely esterified to the cell membrane phospholipid and they participate in signal transduction directly or, after enzymatic conversion, they are transformed in a variety of lipid mediators. Thus, these bioactive lipid derivatives regulate numerous processes within the CNS, including neurotransmission, cell survival, and neuroinflammation ([@B12]). Otherwise, fatty acids can also influence brain function through modulation of the endocannabinoid system, a signaling system with a broad spectrum of biological functions.

Acylethanolamides are synthesized by sequential catalyses following a classical "transacylation-phosphodiesterase pathway" from glycophospholipids. Primarily, a cAMP and Ca^2+^-dependent *N*-acyltransferase (NAT) generates *N*-acylphosphatidylethanolamine (NAPE) ([@B25]) and, subsequently, a non-selective NAPE-hydrolyzing phospholipase D (NAPE-PLD) releases acylethanolamide together with a phosphatidic acid molecule ([@B124]). However, there are secondary pathways to this canonical biosynthesis, for example through a double *O*-deacylation of NAPE to generate NAE by the enzyme α/β-hydrolase domain-containing protein 4 (ABDH4) ([@B166]; [@B182]; Figure [2](#F2){ref-type="fig"}).

Regarding the degradation, acylethanolamides are rapidly inactivated by a process that includes reuptake and hydrolysis, although only the hydrolytic step has been well-characterized. The hydrolysis of acylethanolamide to free fatty acid and ethanolamine is a major pathway that is mainly performed by a membrane-bound fatty acid amide hydrolase (FAAH), which is localized in the endoplasmic reticulum ([@B36]). In addition to the original FAAH (designated FAAH-1), an isozyme of FAAH (FAAH-2) has been identified in human lipid droplets but not in rodents ([@B192]). Other enzymes such as COX-2 and lipoxygenases, which participates in inflammatory functions, are able to inactivate these acylethanolamides by oxygenation ([@B182]; Figure [2](#F2){ref-type="fig"}). Nevertheless, a growing body of evidence has demonstrated the existence of alternative enzymes and pathways for acylethanolamide metabolism, such as Ca^2+^-independent NAT enzymes \[(members of the H-RAS-like suppressor subfamily (HRASLS) and phospholipase A/acyltransferase (PLA/AT)\], NAPE-PLD independent multistep pathways via *N*-acylated lysophospholipid, and the hydrolytic enzyme *N*-acylethanolamine-hydrolyzing acid amidase (NAAA) that preferentially hydrolyzes PEA ([@B182]).

Unlike AEA, the other acylethanolamides OEA and PEA do not bind to cannabinoid receptors, despite PEA was initially described as a potential CB~2~ receptor agonist. The biological functions of these acylethanolamides appear to be mainly mediated by activating PPARα ([@B59]; [@B99]), although PEA has lower potency as agonist than OEA. However, the presence of other acylethanolamides has been known to enhance AEA activity at both cannabinoid and vanilloid receptors by an "*entourage effect*" ([@B169]; [@B80]). Interestingly, PEA activity at PPARα is efficacious to induce antinociceptive effects but not to induce satiety ([@B100]), whereas OEA is more potent as PPARα activator and exerts weaker antinociceptive effects than PEA ([@B173]).

In addition to PPARα, acylethanolamides can modulate other targets such as PPARγ or PPARδ isoforms ([@B59]; [@B137]), other non-cannabinoid GPCRs (e.g., GPR55 and GPR119) ([@B129]; [@B66]), or the transient receptor potential vanilloid type-1 (TRPV-1) ([@B185]; [@B4]). It is to note that there are physiological actions induced by acylethanolamides that are not explained by a modulation of these targets previously commented and, consequently, new targets should be possibly elucidated in the next few years.

Anti-inflammatory and Neuroprotective Actions of Acylethanolamides
------------------------------------------------------------------

As mentioned in the section "Introduction: conceptualization of neuroinflammation and its relationships with neuropsychiatric disorders," chronic neuroinflammation is a common characteristic of a broad range of dysfunctions including psychiatric disorders, neurodegenerative disorders, ischemia, hypoxia, trauma, brain aging and infection, and, for our purposes, even addictive disorders, which result in brain damage \[for review see [@B167] and [@B78]\]. The following paragraphs refer to the evidence in favor of an anti-inflammatory and neuroprotective role of acylethanolamides in such brain disorders.

Emerging evidence supports the relevance of acylethanolamides in neuroinflammation. Several studies have shown that stimulated glial cells produce these lipid mediators ([@B190]; [@B118]; [@B167]). The endogenous levels of acylethanolamides are upregulated in several CNS pathologies, such as multiple sclerosis ([@B10]), stoke ([@B163]), ischemia ([@B43]), Huntington's disease ([@B19]), stress and depression ([@B79]), post-traumatic stress disorder ([@B76]), Parkinson's disease ([@B68]), etc.

A recent study demonstrated that the pharmacological inhibition of FAAH and subsequent increase of AEA, PEA, and OEA in the rat brain produce an attenuation in the expression of cytokines and glial mediators following a systemic administration of LPS ([@B77]). This anti-inflammatory actions of the acylethanolamides are associated with reduction in anhedonia, although they didn't block LPS-induced acute sickness behavior ([@B77]). Interestingly, a gradient release of AEA, PEA, and OEA was found by cerebral microdialysis in a patient suffering with hemispheric stroke, with less concentration of AEA and higher concentrations of OEA in the lesioned area, highlighting the neuroprotective homeostatic role of OEA against the other acylethanolamides ([@B163]).

Finally, it is to note that the neuroprotective actions of acylethanolamides could not be restricted to their brain release, since they rapidly cross the BBB after systemic administration ([@B9]; [@B67]). In this regard, the exogenous peripheral administration of PEA and OEA exerts neuroprotective effects in several models of brain injury and neurological disorders \[for review see [@B78]\].

Target Receptors for Acylethanolamide-Induced Anti-inflammatory Actions
-----------------------------------------------------------------------

Acylethanolamides may exert neuroprotective actions by several mechanisms involving both receptor activation and interaction with other signaling pathways related to the regulation of neuroinflammation. Among these signaling pathways, TLRs have emerged as central keys in the innate immune and neuroimmune responses. As mentioned before, TLRs are activated by PAMPs and they are highly expressed in glial cells ([@B85]). Their activation lead to intracellular signaling cascades involving several kinases \[e.g., MAPKs and tumor growth factor-β-activated kinase 1 (TAK1)\] that converge in the transcription of pro-inflammatory genes by activating the NF-κB and AP-1 ([@B1]). LPS acts as the prototypical endotoxin because it binds to TLR4 as agonist and promotes an inflammatory response through NF-κB activation ([@B111]). Acylethanolamides may directly interfere with the TLR4 signal transduction (i.e., NF-κB), but also may act indirectly suppressing the production of pro-inflammatory cytokines through multiple mechanisms such as the induction of apoptosis, as an immunosuppressive mode of action, or the induction of inhibitory signals \[e.g., anti-inflammatory cytokines (IL-10) and IL-1 receptor antagonist\] \[for review see [@B111]\].

In addition to TLRs, cannabinoid and non-cannabinoid receptors for acylethanolamides are also expressed in glial cells, and their ligands have been shown to negatively modulate TLR-induced neuroinflammation in these cells ([@B159]). There is evidence that activation of immune cells by inflammatory stimuli modulates the expression of both subtypes of cannabinoid receptors, a fact that has been associated with immune-regulatory effects of cannabinoids ([@B159]). Several studies have reported that endocannabinoids inhibit the formation of pro-inflammatory cytokines in both human cell cultures and animal models, but the interplay between the signaling pathways of the cannabinoid receptors and TLRs needs to be considered for a better comprehension.

The anti-inflammatory actions of AEA can be related to its ability to inhibit 2-AG metabolism and effects ([@B103]), since 2-AG signaling appears to be the primary responsible for maintaining integrity and homeostasis of brain function ([@B195]). Microglial cells express high levels of CB2 receptor in patients with neurological disorders (e.g., multiple sclerosis and Alzheimer's disease) ([@B13]; [@B196]). Indeed, a recent study showed that AEA attenuates LPS-induced neuroinflammation (based on NO production) in microglial cultures via CB~2~ receptors ([@B105]). Thus, while the administration of a CB~2~ receptor antagonist partially prevented the neuroprotective effects of AEA on microglia, CB~1~ or GPR55 antagonists have no effects. Nevertheless, CB~1~ receptors also participate in neuroinflammation regulation. For example, AEA inhibits the expression of endothelial receptors related to leukocyte transmigration in multiple sclerosis through CB~1~ receptor ([@B69]). Furthermore, the activation of CB~1~ receptors modulates stress-induced conditions and neuroinflammation through several mechanisms, including the inhibition of inflammatory response genes via NF-κB and enzymes such as inducible iNOS and COX-2 ([@B200]).

The activation of PPARα and other isoforms modulates oxidative stress, neurotransmission, neurogenesis, glial cell proliferation/differentiation, and neuroinflammation ([@B57]) through negative transcriptional regulation of inflammatory response genes. A study in rats from our lab showed that OEA and PEA prevent LPS-induced NF-κB activation, the expression of iNOS and COX-2, accumulation of NO, and lipid peroxidation in the frontal cortex ([@B162]). However, to date, it is unproven that this brain anti-inflammatory effects are directly mediated or not by PPARα receptors. PEA has been proven to exert anti-inflammatory effects in ischemia through an intracellular mechanism independent of known acylethanolamides receptors ([@B65]).

Finally, TRPV-1 appears to play a bidirectional role in the modulation of inflammatory cytokines. TRPV-1 has been reported to be functionally expressed in rodent and human glial cells ([@B107]). TRPV-1 activation promotes Na^+^ and Ca^2+^ influx and membrane depolarization, and directly affects cellular responses such as proliferation, migration, release of inflammatory cytokines, and oxidative stress. Several studies show that TRPV-1 regulates synaptic transmission and plasticity in neurons and interacts with pro-inflammatory cytokines. A growing body of recent literature supports that TRPV-1 activation induces an amplification of pro-inflammatory responses, whereas TRPV-1 inhibition reduces the release of cytokines and neurotoxicity ([@B83]; [@B158]). Therefore, TRPV-1 activation leads to aggravate the inflammatory response in certain neurological diseases (e.g., experimental autoimmune encephalomyelitis, epilepsy, and brain ischemia) ([@B93]). In contrast, other studies indicate a protective role of TRPV-1 in neurological diseases. Thus, agonists of TRPV-1 have been shown that act as anti-inflammatory and immunomodulatory agents by inhibiting pro-inflammatory cytokines (e.g., TNF-α, IL-1β, and IL-17) ([@B181]). Moreover, TRPV-1 also showed protective roles in vascular dementia and Huntington's disease by inhibiting oxidative stress ([@B71]; [@B72]). Additional mechanisms to reduce inflammation by modulating inflammatory signaling pathways have been suggested. For example, vanilloids can inhibit LPS-induced production of NO and regulate protein and gene expression of iNOS and COX-2 ([@B28]).

A potential explanation of these paradoxical effects is associated with a desensitization of TRPV-1. There is evidence of TRPV-1 sensitization by inflammatory mediators (e.g., cytokines, chemokines, neurotransmitters, lipids, and growth factors) direct or indirectly, inducing strengthen TRPV-1 activity. Thus, several studies have reported the existence of co-expression and functional association between TRPV-1 and receptors of these inflammatory mediators, which can regulate the conductance and trafficking of TRPV-1. Therefore, cytokines can interact with their specific GPCRs, which phosphorylate TRPV-1 and induce changes in intracellular Ca^2+^-dependent signaling pathways such as protein kinases. These changes lead to the downstream activation of transcriptional pathways such as NF-κB and STAT3 ([@B93]).

All these data suggest that several pro-inflammatory signaling pathways are susceptible to be modulated by acylethanolamides through a direct interaction with receptors such as CB receptors, PPARs and TRPVs, but also through an influence on primary intracellular cascades controlled by TLRs in glial cells, which converge in the regulation of pro-inflammatory genes via transcription pathways such as NF-κB.

Mechanisms by Which OEA Reduces Alcohol-Induced Neuroinflammation
=================================================================

Exogenous administration of OEA has proven to exert potent anti-inflammatory, antioxidant, and neuroprotective effects in animals exposed to alcohol binges ([@B5]). Specifically, OEA pre-treatment before alcohol binges inhibits alcohol-induced increases in TLR4 expression (Figure [3A](#F3){ref-type="fig"}) and activation of the NF-κB canonical inflammatory pathway. As a result, OEA inhibits the release of the pro-inflammatory cytokine IL-1β, chemokine MCP-1, and danger molecule HMGB1 (Figure [3B](#F3){ref-type="fig"}), and the activity of the enzymes COX-2 and iNOS, preventing ethanol-induced lipid peroxidation and apoptotic mechanisms in prefrontal cortex ([@B5]; Figure [1](#F1){ref-type="fig"}). The mechanisms by which OEA reduce innate immunity activation and neuroinflammation induced by alcohol abuse are discussed in the following lines.

![Effects of OEA in cortical TLR4 expression by western blot analyses **(A)** and cortical HMGB1 release by enzyme-linked immunosorbent assay **(B)** in alcohol binge-exposed rats. Modified from [@B5].](fnmol-11-00490-g003){#F3}

OEA in Alcohol Metabolism
-------------------------

Since ethanol administration induces a rapid release of OEA in the intestine and liver (remember that also in the brain), it could be argued that the satiety factor OEA interferes in the absorption of ethanol. Lower blood ethanol levels would mean decreased ethanol-induced effects, including its action on immune receptors and inflammation. However, the exogenous administration of OEA does not modify blood ethanol levels in animals exposed to alcohol binge intoxication ([@B5]), indicative that this is not the protective mechanism of OEA against alcohol actions.

OEA as a PPARα Agonist
----------------------

Oleoylethanolamide crosses the BBB reaching the brain rapidly after i.p. administration ([@B140]; [@B67]) to exert its actions. The anti-inflammatory actions of OEA could be related to its PPARα agonism within the brain, since activation of this nuclear receptor has been shown to induce changes in inflammatory-related genes by repressing the nuclear factors NF-κB and AP-1 (reviewed in [@B172]). However, a direct evidence of the PPARα involvement in OEA-mediated inflammatory actions has not been provided and, indeed, recent reports indicate that endogenous elevations of AEA, OEA, and PEA regulate TLR4-associated neuroinflammation partially through brain TRPV1 but not PPAR receptors ([@B77]).

Peripheral Inflammation and Brain Homeostasis
---------------------------------------------

Another plausible mechanism to explain the OEA-induced reduction in neuroinflammation is the anti-inflammatory actions that this biolipid exerts at peripheral level, since the effects of OEA in pro-inflammatory cytokine reduction have been observed both at central and peripheral levels ([@B5]). As pointed out in the section "Alcohol Abuse and Neuroinflammation," systemic immune activation may promote neuroinflammation through different pathways. On the one hand, the sympathetic activity of peripheral pro-inflammatory cytokines activates HPA axis by vagus nerve afferent stimulation and transmits cytokine signals to the brain ([@B81]). On the other hand, peripheral cytokines can reach the brain by the circumventricular organs and/or through saturable cytokine transporters at the BBB, affecting brain homeostasis \[reviewed in [@B41]\]. Then, it could be possible that inhibition of alcohol-induced peripheral inflammation by OEA accounts for a reduction in neuroinflammation associated with drug abuse. Specific studies to isolate peripheral from central effects would be needed to ascertain this point.

Effects in the Blood--Brain Barrier
-----------------------------------

An increased peripheral inflammatory response could alter the permeability of the BBB ([@B186]), so the ethanol-induced peripheral inflammation could be a risk factor to BBB dysfunction. The main function of the BBB is to protect the CNS from circulating toxins in order to maintain the internal homeostasis. Thus, the infiltration of pathogen molecules or bacterial products from the periphery would make the brain more vulnerable to damage. It has been proven that certain drugs of abuse may alter the structure and functioning of the barrier, including alcohol. Evidence of the BBB disruption and neuroinflammation was shown in *postmortem* alcoholic brains ([@B155]). The strong anti-inflammatory properties of OEA in the periphery could account for the protective action in the brain, since it could preserve the cytokine-mediated BBB disruption. Alternatively, OEA could have a direct action in the structure of the BBB, protecting alcohol-induced damage in proteins of the basal lamina around the pericytes and endothelial cells. However, a direct action of OEA on the proteins that conform the BBB has not yet been investigated and this hypothesis remains at present speculative.

Effect in the HPA Axis
----------------------

It is well known that alcohol modulates the HPA axis, inducing stress-related neuroendocrine adaptations. Acute alcohol activates HPA axis, whereas chronic alcohol consumption may induce tolerance to this effect, blunting the HPA axis over a long-term period ([@B3]). Glucocorticoids, as final effectors of the HPA axis activation, are important regulators of inflammation, since they are known to exert anti-inflammatory properties by negative regulation of the TLR4/NF-κB pathway, controlling the immunity response. In this regard, an important action of OEA is the reduction of ethanol-induced rise in blood corticosterone levels in rats ([@B5]). Elevation in blood corticosterone levels occurs also after experimental simulation of neuroinflammation by systemic administration of LPS, but by contrary, OEA did not revert LPS-induced rise in corticosterone levels ([@B162]). These differential effects of OEA on corticosterone levels depending on the cause that induces the rise (ethanol or LPS) are very intriguing and deserve further investigation, but could be related to the different length of OEA administration in each study (subchronic repeated OEA injections in the ethanol study *versus* acute administration in the LPS study). Nevertheless, the inhibition of blood corticosterone levels induced by OEA may be protective for the neurodegeneration induced by ethanol, since elevated circulating corticosterone partially mediates ethanol binge-induced neurotoxicity ([@B31]).

Innate Immunity Receptors TLR4 and HMGB1 Release
------------------------------------------------

Among the factors that induce the strong immune activation caused by alcohol abuse are: (1) a TLR4 direct agonism; (2) the upregulation of plasma LPS, which is also a TLR4 agonist; and (3) the overproduction of DAMPS such as HMGB1, which magnifies TLR4 activation (Figure [1](#F1){ref-type="fig"}). It has been shown that OEA reduces the expression of TLR4 innate immune receptors and its signaling pathway both in the brain and in the gut after ethanol binges ([@B39]; [@B5], [@B7]). Regarding the increase of plasma LPS, it is very interesting to note that pretreatment with OEA appears to modulate, at least partially, the alcohol-induced increase in plasma levels of LPS ([@B5]), reducing the TLR4 activation and inflammation. Regarding the overproduction of DAMPS, alcohol abuse has been shown to induce the release of HMGB1 in several brain areas in animals and humans, as explained in the section "Alcohol Abuse and Neuroinflammation," of this review, presumably as a consequence of the TLR4 signaling pathway activation ([@B5],[@B6]). This HMGB1 is also a TLR4 agonist and activator of neuroimmune genes, and amplifies the inflammatory response in a vicious cycle. It is to note that young female binge drinkers' show elevated plasma HMGB1 levels that correlate with circulating levels of OEA. In rats, pretreatment with OEA reduces HMGB1 in cortical samples of alcohol binge exposed animals, which could be the origin or consequence of the reduced TLR4-associated neuroinflammation observed after OEA treatment ([@B5]).

Oxidative Stress
----------------

Mechanisms by which ethanol injures the brain include inflammation-derived oxidative stress. In this way, the over-activation of TLR4/NF-κB pro-inflammatory pathway produces oxidative/nitrosative stress, increasing lipid peroxidation in different neuroinflammatory conditions (e.g., stress, LPS, alcohol). This oxidative stress is known to be the consequence of an exacerbated inflammation, but molecules derived from lipid peroxidation and cell damage can also upregulate the inflammatory cycle in a vicious cycle inducing more neuroinflammation. For example, as a consequence of TLR4/NF-κB activation, alcohol abuse induces oxidative stress and redox status-dependent caspase 8 synthesis, which is an upstream intermediate in the caspases' cascade for apoptosis cell death. In response to damaged tissue, HMGB1 can be released overactivating the proinflammatory TLR4/NF-κB pathway in a vicious cycle, as mentioned before (Figure [1](#F1){ref-type="fig"}). The anti-oxidant actions of OEA in the rat brain under inflammatory conditions have been shown by us and other authors, since OEA is able to reduce LPS- or alcohol-induced malondialdehyde and/or 4-hydroxynonenal accumulation (lipid peroxidation bioproducts) in rat frontal cortex ([@B87]; [@B162]; [@B5]). This antioxidant effect of OEA is accompanied by reductions in caspase-8 and caspase-3 activity and less HMGB1 accumulation, reducing, presumably, the TLR4/NF-κB pathway activation ([@B5]).

The antioxidant properties of OEA are multifaceted, as it has been shown in a primary cultured human umbilical vein endothelial cell (HUVEC) H~2~O~2~-induced injury model where OEA acted as scavenger for ROS, as well as increased anti-oxidative enzymes ([@B101]). More specifically, another *in vitro* study showed that OEA and other *N*-acylethanolamides protected plasma lipoproteins against lipid peroxidation and preserve the activity of the plasma antioxidant enzyme paraoxonase (PON1) from oxidative inactivation ([@B199]).

Alcohol abuse activates innate immune genes including the NADPH oxidase, an enzyme that produces ROS, inducing oxidative stress and contributing to cell damage ([@B146]; [@B145]). As of this writing, a direct implication of OEA in NADPH activity has not been tested yet.

Protective Actions in the Intestinal Barrier
--------------------------------------------

Alcohol abuse damages the gastrointestinal barrier, allowing the entry of microorganisms and bacterial products, such as LPS, to inner organs and/or the systemic circulation. This phenomenon, called *leaky gut*, has been demonstrated in experimental models of chronic alcohol intake and in alcohol-dependent subjects ([@B90]; [@B95]). As a consequence of this *leaky gut* phenomenon, and as we mentioned before, alcohol induces the rise in blood LPS, a component of the wall of Gram-bacteria, which is able to activate TLR4 receptors as an agonist inducing the activation of the inflammatory NF-κB pathway. Alcohol may induce such effect by paracellular or by transepithelial mechanisms. Paracellular mechanisms involve a dysfunction in the tight junction (TJ) proteins of the gut epithelial cells, so the molecules accede the bloodstream through the junctions between cells. Transepithelial mechanisms refer to the pass of substances because of oxidative stress-induced damage or weakness of cell membranes ([@B18]).

Interestingly, we recently found that OEA pretreatment reduces alcohol-induced elevations in circulant LPS, a reduction that is partial under intraperitoneal (i.p.) treatment ([@B5]) and almost total under oral OEA administration ([@B7]). The origin of such decrease in plasma LPS levels could be a direct action of OEA in the intestinal barrier, modulating gut inflammation and bacteria/bacterial products translocation from the intestinal lumen to the systemic circulation ([@B7]).

Recent evidence suggests that elevated inflammation in the gut combined with high levels of oxidative/nitrosative stress affect epithelial junctional complexes such as TJ proteins, and contribute to gut leakiness and elevations in serum endotoxin levels ([@B138]; [@B30]). In this sense, our recent study shows that OEA exerts a potent anti-inflammatory action in the gut after alcohol binge drinking, reducing colonic TLR4 expression and oxidative/nitrosative stress. Interestingly, OEA i.p. pre-treatment partially counteracts the alcohol-induced damage to the intestinal barrier, since the integrity of some colonic TJ proteins, such as claudin-3 and occludin, is preserved in OEA-pretreated animals ([@B7]). In the same study, we did not find an effect of OEA in alcohol-induced gut cell apoptosis, indicative that OEA reduces alcohol-induced paracellular but not transepithelial mechanisms in the colon.

Although the anti-inflammatory and TJ protectant actions of i.p. OEA were clear in a binge alcohol model, reduction of alcohol-induced LPS was partial and modification in alcohol-induced translocation of bacteria was not evident (not significant). This is probably due to the convergence of paracellular and transepithelial mechanisms after an aggressive binge alcohol protocol. However, an oral pretreatment with OEA reduces the bacterial translocation from intestinal lumen to mesenteric lymph nodes and the rise in plasma LPS after ethanol binges, which could be an unquestionable focus for its anti-inflammatory activity ([@B7]). The differences between i.p. and oral administration modulating paracellular and transepithelial mechanisms in the gut after alcohol administration are unknown and deserve further investigation.

Microbiome and Gut--Brain Axis Modulation
-----------------------------------------

There is an emerging *hot topic* in the scientific community trying to understand neuropsychological and neuropsychiatric disorders from a holistic perspective, avoiding an exclusive brain-related point or view to clear the way out for a role of the human gut microbiome in the etiology and pathogenesis of such disorders. The influence of the gut microbiota is being explored for many neuropsychiatric conditions and this psychoneuroimmunology approach is extending to the drug addiction field as well. Growing evidence indicates that there is a bidirectional communication between gut microbiota and the brain affecting the CNS functioning with consequences in cognition, emotion, and behavior (reviewed in [@B160]). This gut--brain axis appears to be dysregulated in several brain pathologies, inducing an exacerbated inflammatory response that may ultimately affect the brain. However, we are still far away from the understanding of a role for bacteria signaling, if any, in alcohol responses, including neuroinflammation.

In this regard, very recent studies point out to a role of OEA modulating gut microbiota composition in mice under physiological conditions ([@B45]), polarizing gut-specific immune responses. The study of OEA effects in the gut microbiome altered by alcohol and its relationship with immune and inflammatory responses is still pendent by the scientific community.

Effects of OEA in Alcohol Consumption and Negative Behaviors Associated With the Abstinence
===========================================================================================

OEA Decreases Alcohol Intake and Relapse
----------------------------------------

The beneficial actions of OEA in alcohol abuse have been tested in animal models of chronic alcohol consumption ([@B17]) and binge drinking ([@B5]). Regarding chronic alcohol consumption, OEA was able to decrease alcohol self-administration relative to controls at doses of 5 and 20 mg/kg i.p. In a two-bottle choice paradigm, OEA-treated animals showed decreased voluntary drinking relative to controls at different time points, indicating that OEA serves as a regulator of voluntary alcohol intake (Figure [4](#F4){ref-type="fig"}).

![Effect of oleoylethanolamide (OEA) in alcohol self-administration **(A)** and alcohol drinking in a two-bottle choice paradigm **(B)**. Modified from [@B17].](fnmol-11-00490-g004){#F4}

Oleoylethanolamide decreased also alcohol-induced operant responses after a period of drug deprivation, with has important implications for relapse to alcohol. Specifically, OEA was capable of blocking cue-conditioned reinstatement of alcohol-seeking behavior, an animal model of relapse ([@B17]).

Mechanisms by Which OEA Reduces Alcohol Consumption
---------------------------------------------------

It is not clear enough and a focus of debate whether the alcohol-induced neuroinflammation would play a role in alcohol consumption. Some studies fail to detect a link between alcohol-induced neuroinflammation and drug consumption ([@B94]), and genetic and pharmacologic manipulation of TLR4 has been shown to have a minimal impact on rodent ethanol consumption ([@B75]). On the contrary, recent studies using anti-inflammatory mesenchymal stem cells suggest that targeting neuroinflammation could be an effective therapeutic approach to reduce alcohol consumption and relapse ([@B52], [@B53]).

In this regard, it is to note that OEA affects also the self-administration of sucrose, so it may affect general motivational processes. Alcohol is both a high-calorie food and a drug of abuse and, therefore, capable of modulating the reward system. In this sense, OEA might serve to modulate motivational drives associated with food selection through an ability to modulate the brain reward system ([@B178]). Indeed, it has been described that OEA modulates nicotine-induced activation of mesocorticolimbic dopaminergic neurons ([@B115]; [@B108]). It is also possible that OEA affects cognitive processes associated with the hedonic value of behaviors, since OEA appears to modulate memory consolidation ([@B27]).

Inspite of that, OEA appears to reduce food intake through a peripheral mechanism ([@B151]) and, similarly, to decrease alcohol intake through activation of the vagus nerve ([@B17]). In detail, [@B178] showed that intestinal OEA modulates vagus nerve terminals in the gut affecting the dopaminergic activity in the reward system and that exogenous administration of OEA restored the dopamine deficiency associated with high-fat diets ([@B178]). Regarding alcohol intake, deafferentation of gut vagal afferents with the neurotoxin capsaicin abolished the reduction in alcohol self-administration induced by OEA ([@B17]), suggesting that the modulation of voluntary alcohol consumption by OEA initiates its action in the gut. In favor to this hypothesis is the fact that direct administration of OEA in the brain was not able to alter alcohol self-administration, inspite of OEA levels increase in the brain (nucleus accumbens) after ethanol administration.

The mechanisms by which OEA reduces voluntary alcohol consumption and alcohol relapse have been studied. As mentioned before, OEA is a PPARα agonist and a great deal of its effects are absent in PPARα knock-out mice ([@B59]; [@B73]). Then, the effects of OEA on alcohol consumption have been compared with the effects of PPARα agonists and antagonists. The i.p. injection of Wy14643, a PPARα agonist, imitated the actions of decreasing alcohol self-administration, cue-induced reinstatement, or alcohol deprivation effect, and the compound GW6471, a PPARα antagonist, reverted the actions of OEA decreasing alcohol intake in the two-bottle choice paradigm. Additionally, deafferentation by capsaicin reverted the actions of Wy14643 on self-administration, similar to the OEA-induced effects.

OEA Decreases Alcohol Withdrawal-Induced Negative Emotional Behaviors
---------------------------------------------------------------------

Oleoylethanolamide and other acylethanolamides, as mentioned before, display antioxidant and anti-inflammatory properties ([@B44]; [@B22]), both of which can also have a profound impact on brain and behavior ([@B15]; [@B130]; [@B170]). For example, inflammatory processes are attributed an important role in the pathophysiology of key manifestations of multiple psychiatric disorders such as anhedonia or deficits in motivation, and those manifestations can be readily induced by the former ([@B150]; [@B174]). OEA, but not PEA, improves anhedonia in a murine model of neuroinflammation, and this improvement appears to be mediated by its anti-inflammatory properties ([@B162]; Figure [5](#F5){ref-type="fig"}). In this line, OEA induces improvements in depression indexes such as increased swimming time in the behavioral despair test after alcohol binge-induced brain damage and neuroinflammation ([@B5]; Figure [6](#F6){ref-type="fig"}).

![Anti-anhedonic effects of OEA in the saccharine preference test 24 h **(A)** and 30 h **(B)** after LPS administration. Modified from [@B162].](fnmol-11-00490-g005){#F5}

![Antidepressant actions of OEA in the forced swimming test after alcohol binges. OEA pretreatment increases the time in which the animals try to escape **(A)** and the latency **(D)** to stay immobile, reducing immobility **(C)**, which is a sign of behavioral despair induced by alcohol binges. OEA did not significantly affect ethanol-induced decrease in climbing **(B)**. Retrieved from [@B5].](fnmol-11-00490-g006){#F6}

Exacerbated neuroinflammation (e.g., by LPS administration) induces sickness behavior, which is evaluated by acute-phase responses, such as activation of HPA axis, body temperature regulation, anhedonia, or behavioral despair. Hyperactivity in the HPA axis has long been linked to anxiety and stress disorders (see [@B8]). OEA administration is able to normalize the hyperactivity of the HPA system in a mice model of chronic mild stress, or after alcohol binge drinking, along with the reversal of behavioral markers of stress such as reduced sucrose drinking or exploratory activity ([@B87]). The integrity of PPARα and histamine receptors appears to be indispensable for OEA antidepressant effects to take place, as mice deficient for these receptors does not show improvements in mobility time in the tail suspension test or enhanced exploratory time in an open field ([@B35]).

Hypothermia is an adaptive response to combat acute inflammation and enhance survival ([@B104]). OEA pre-treatment potentiates the hypothermic acute response after LPS administration and counteracts LPS-induced increases in hypothalamic pyrogen-related molecules such as IL-1β, COX-2, and PGE2. Then, OEA has been proven to modulate acute-phase responses after LPS-induced neuroinflammation, including temperature regulation, HPA axis activation, and motivational arousal ([@B162]).

Lipopolysaccharide-induced neuroinflammation is associated also with learning and memory deficits in rodents ([@B157]) and it is well known that the effect of alcohol abuse in memory impairments. OEA appears to have a beneficial role in memory consolidation, through activation of PPARα receptors in the periphery ([@B27]; [@B144]). OEA may modulate also emotional memory tasks such as the contextual fear conditioning, which appears very relevant as this behavioral paradigm is generally considered to have substantial coincidences with functional and neural mechanisms involved in anxiety and various other mental disorders ([@B153]; [@B23]), including alcohol addiction.

Oleoylethanolamide and other cannabinoid-like compounds have been proposed for the treatment of anxiety disorders and one of the mechanisms by which this compound could have a beneficial impact on anxiety could be slowing down of AEA degradation by competing with it for FAAH activity ([@B177]). FAAH inhibition has been shown to exert rapid and long-lasting anti-anxiety effects in behavioral paradigms such as acute inescapable stress or chronic corticosterone administration, but the specific mechanisms are still not well understood ([@B48]). Curiously, FAAH inhibition has also been shown to enhance memory acquisition, possibly through the activation of PPARα receptors ([@B110]). Anyhow, OEA shows clear antidepressant and anti-anxiety properties and this line of intervention is thought to have lower unwanted effects than traditional anti-anxiety drugs ([@B87]; [@B48]).

Emotional arousal, memory, and learning or motivational behavior are aspects of high relevance in the field of alcohol abuse. OEA modulates also other behaviors related with alcohol withdrawal symptoms, such as vocalization, tremors, or paw rigidity, with a significant reduction in the global ethanol withdrawal scores ([@B17]; Figure [7](#F7){ref-type="fig"}).

![Effect of OEA reducing ethanol withdrawal scores. Retrieved from [@B17].](fnmol-11-00490-g007){#F7}

Conclusion and Clinical Relevance: the Homeostatic Role of OEA in Alcohol Abuse
===============================================================================

Data presented in this review indicate that OEA has a beneficial role to counteract many responses related to alcohol consumption and abuse, so OEA-based pharmacotherapies emerge as future perspectives to treat AUDs.

In line with the results presented in this review, OEA can be considered as an endogenous signal with a homeostatic role in the organism. This is supported by the observed increase in OEA levels in the brain and periphery after insults to the CNS that curse with neuroinflammation, and by its anti-inflammatory and protective effects in many CNS disorders, including Parkinson's disease ([@B67]), autoimmune encephalomyelitis ([@B46]), multiple sclerosis ([@B147]), ischemia ([@B198]), anhedonia ([@B162]), and cocaine, nicotine, or alcohol addiction ([@B115]; [@B16], [@B17]; [@B5]).

In particular, there is strong evidence that endogenous OEA is released as counteracted response to alcohol abuse. First of all, animal studies showed that acute i.p. administrations of ethanol induce a rapid release of OEA (in 45--90 min) in the small intestine, the liver, and also in brain areas such as the nucleus accumbens and cerebellum. Elevations of OEA in plasma after alcohol i.p. administration occurred in an interval of 90--240 min, parallel to the time in which blood alcohol levels are elevated after the administration. Chronic alcohol consumption maintains elevated levels of OEA in plasma during the alcohol liquid diet that remains elevated in the period in which blood ethanol levels are detectable (6 h of withdrawal approximately). Thus, the presence of OEA in blood persisted, at least, as long as the ethanol is also present, and starts to decrease after removing alcohol ([@B56]; [@B17]), strengthening the homeostatic role of OEA in the organism.

Secondly, results in animals are in agreement with recent studies in alcohol-dependent patients. OEA concentration was found elevated during early abstinence in those patients relative to controls, and the concentration of OEA was gradually decreasing as advanced the duration of abstinence, approaching the control group ([@B64]). Thus, OEA plasma levels were negatively correlated to the duration of abstinence, suggesting that OEA may serve also as a potential marker to predict length of alcohol abstinence.

Thirdly, human studies revealed that OEA is released after different patterns of alcohol or cocaine abuse, and correlates with inflammatory markers. For example, regular alcohol binge drinkers showed during abstinence elevated plasma levels of OEA and other related biolipids, compared with little or no drinkers ([@B7]). These elevated levels of OEA correlate with key peripheral inflammatory makers found in these young drinkers, such as the innate immunity receptors TLR4, pro-inflammatory cytokines IL-1β and IL-6, or pro-inflammatory enzyme COX-2 ([@B127]; [@B7]). Higher plasma HMBG1 and other pro-inflammatory cytokines correlate with worse scores on episodic memory and executive functioning task in female regular binge drinkers and, interestingly, that increase in the danger-related molecule HMGB1 correlates also with OEA plasma levels in such female binge drinkers ([@B6]), in favor of the mentioned homeostatic role of OEA.

In summary, preclinical and clinical evidence point-out to the beneficial actions of OEA to treat many negative aspects of alcohol abuse, including neuroinflammation, cognitive decline, withdrawal responses, or motivation and relapse to drinking. OEA-based pharmacotherapies emerge as future perspectives to treat AUDs.
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